Evidence map›Paper›PMID 38044650›Full record

ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences

Adeno-associated virus-mediated gene therapy for rare pediatric neurogenetic diseases: Current status and outlook.

Xiaole Wang, Xueqin Lin, Hailan He, Jing Peng

Open access · greenAbstract read
In one paragraph

Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Xiaole WangDepartment of Pediatrics, Xiangya Hospital, Central South University, Changsha 410008. wangxl315@csu.edu.cn.
Xueqin LinDepartment of Pediatrics, Xiangya Hospital, Central South University, Changsha 410008.
Hailan HeDepartment of Pediatrics, Xiangya Hospital, Central South University, Changsha 410008.
Jing PengDepartment of Pediatrics, Xiangya Hospital, Central South University, Changsha 410008. pengjing627@126.com.
Central South University · CNXiangya Hospital Central South University · CN

Funding

the Key Research and Development Program of Hunan Province 2022SK2036
6 · The paper itself

Abstract

Rare pediatric neurogenetic diseases always have early onset, no specific therapy, high mortality, and pose a severe risk to the health and survival of children. Adeno-associated virus (AAV)-mediated gene therapy, a type of disease-modifying therapy, provides a new option for the treatment of rare pediatric neurogenetic diseases and represents a significant advancement in the field. Currently, the US Food and Drug Administration (FDA) and the European Medicines Association (EMA) have approved AAV-mediated gene therapy medications for treating spinal muscular atrophy, aromatic

Indexed as

DependovirusMuscular Dystrophy, DuchenneChildGenetic TherapyGenetic VectorsHumansRare DiseasesUnited Statesadeno-associated virusgene therapyrare pediatric neurogenetic diseases

Identifiers

PMID38044650
PMCPMC10929874
OpenAlexW4389315584

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.